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Circulating Th17, Th22, and Th1 Cells Are Increased
in Psoriasis
Shinji Kagami1, Heather L. Rizzo1, Jennifer J. Lee1, Yoshinobu Koguchi2 and Andrew Blauvelt1,2,3
Th17, Th22, and Th1 cells are detected in psoriatic skin lesions and implicated in psoriasis pathogenesis, but
inflammatory T cell numbers in blood, as well as the relative importance of each cell type, is unclear. Using
7-color flow cytometry, circulating Th17, Th22, and Th1 cells were quantified in 21 untreated psoriatics and 17
healthy individuals. CCR6 was the best cell surface marker for IL-17Aþ cells when compared with IL-23R or
CD161. CCR6þ , IL-17Aþ , IL-22þ , CCR6þ IL-17Aþ , CCR6þ IL-22þ , CCR6þ tumor necrosis factor-aþ ,
IL-17Aþ IFN-g, IL-17Aþ IL-22þ IFN-g, and IL-17Aþ IL-22IFN-g cells were increased in psoriatics (all values
Po0.001), indicating elevations in circulating Th17 cells, using multiple criteria to define these cells. Th22
(IL-17AIL-22þ IFN-g, Po0.05) and Th1 (IL-17AIFN-gþ , Po0.05) cells were also increased in psoriatics, but to
a lesser extent. Inhibition of either NF-kB or STAT3 in vitro blocked cytokine production by both Th17 and Th1
cells. Circulating levels of Th17 and Th1 cells decreased in a subset of five psoriasis patients serially evaluated
following induction therapy with infliximab. In summary, elevated numbers of circulating inflammatory T cells
may contribute to cutaneous inflammation and systemic inflammatory disease that occurs in individuals with
psoriasis.
Journal of Investigative Dermatology (2010) 130, 1373–1383; doi:10.1038/jid.2009.399; published online 24 December 2009
INTRODUCTION
T-helper (h)17 cells are inflammatory CD4þ T cells that
produce IL-17A and not IFN-g (Miossec et al., 2009). These
cells and the cytokines produced by these cells are found in
increased levels within skin affected by psoriasis (Chan et al.,
2006; Wolk et al., 2006; Wilson et al., 2007; Zaba et al.,
2007; Kryczek et al., 2008; Lowes et al., 2008; Harper et al.,
2009). Th22 cells are recently described inflammatory
CD4þ T cells that produce IL-22, but do not express
IL-17A or IFN-g (Duhen et al., 2009; Liu et al., 2009;
Nograles et al., 2009; Trifari et al., 2009). Th22 cells are also
increased within psoriasis lesions (Harper et al., 2009;
Nograles et al., 2009). Before the discovery of Th17 and
Th22 cells, inflammatory CD4þ T cell studies in psoriasis
focused on Th1 cells, which produce IFN-g as their signature
cytokine. It has been well established for many years that Th1
cells and cytokines are elevated in psoriatic tissue as well
(Uyemura et al., 1993; Szabo et al., 1998; Austin et al.,
1999). As the past and current data show that Th17, Th22,
and Th1 cells are all present within skin tissue affected by
psoriasis, controversy exists as to the relative importance of
each T cell type in disease pathogenesis. Thus, in human
diseases where Th17, Th22, and Th1 cells are believed to
have primary pathogenic roles, such as psoriasis, it is a
fundamental aim of researchers in this field to determine (1)
the relative contribution of each cell type to disease
pathogenesis; (2) whether cell numbers correlate with disease
activity and response to therapies; and (3) whether Th17,
Th22, and Th1 cells are increased throughout the body as
well as within affected tissues or whether these cells are
expanded locally only at disease sites.
To help address these critical questions, identification and
quantification of human Th17, Th22, and Th1 cells by flow
cytometric analyses has been described over the last several
years (Acosta-Rodriguez et al., 2007; Annunziato et al., 2007;
Wilson et al., 2007; Cosmi et al., 2008; Duhen et al., 2009;
Trifari et al., 2009). Th17 cell clones derived through in vitro
differentiation are CCR6þ , and a subset of Th1 clones is also
CCR6þ (Acosta-Rodriguez et al., 2007). Coexpression of
CCR6 and CCR4 as well as expression of IL-23R helped
distinguish Th17 cells from Th1 cells, which were found to be
CXCR3þ and IL-23R (Acosta-Rodriguez et al., 2007).
Annunziato et al. showed that CCR6 expression was much
more commonly expressed by Th17 clones, whereas both this
group and Wilson et al. confirmed that, as expected, IL-23R
was expressed by Th17 clones and not by Th1 clones
(Annunziato et al., 2007; Wilson et al., 2007). CD161 was
more recently shown to be a cell surface marker for Th17
cells (Cosmi et al., 2008); expression of CD161 has not yet
been evaluated in patients with psoriasis. Using mainly
cytokine production to label cells, circulating Th17 cells have
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been reported to be elevated in patients with Crohn’s disease
(Kleinschek et al., 2009), ankylosing spondylitis (Shen et al.,
2009), and rheumatoid arthritis (Shen et al., 2009).
In this study, 7-color flow cytometry was used to identify
and quantify Th17, Th22, and Th1 cells among circulating
primary CD4þ cells isolated from individuals with and
without psoriasis. CCR6, IL-23R, and CD161 were used as
cell surface markers, and intracellular cytokine expression for
IL-17A, IL-22, IFN-g, and tumor necrosis factor (TNF)-a was
assessed. A subset of patients undergoing infliximab therapy
was serially assayed over the initial course of their treatment.
Th17, Th22, and Th1 cells, as defined by a number of criteria,
were clearly increased in blood of psoriatics. Increased
numbers of circulating inflammatory T cell subsets may
contribute to both cutaneous inflammation and to systemic
inflammatory disease as occurs in individuals with psoriasis.
RESULTS
Circulating CCR6þ , IL-23Rþ , and CD161þ CD4þ cells are
increased in psoriasis
Table 1 shows the demographic features of individuals
analyzed in this study. For all experiments, CD4þ cells
were purified from peripheral blood by negative selection
(495% purity, data not shown) and cultured for 1 day with or
without phorbol myristate acetate (PMA) and ionomycin for
the last 6 hours of culture. In single-color flow analyses,
percentages of CD4þ cells that were CCR6þ , IL-23Rþ , or
CD161þ were increased in psoriatics compared with
healthy individuals (16.6±6.44 vs 8.82±3.12%, Po0.001;
19.9±6.36 vs 9.85±5.75%, Po0.01; 14.1±4.33 vs
10.9±4.06%, Po0.05, respectively) (Figure 1a). It is noted
that mitogen activation for 6 hours was found to decrease
CCR6 surface expression (13.2±5.76% unstimulated vs
12.0±5.18% stimulated, Po0.01, n¼ 53), but not IL-23R
(15.6±8.98% unstimulated vs 16.1±6.11% stimulated,
n¼12) or CD161 (12.8±4.58% unstimulated vs
13.1±4.69% stimulated, n¼45) surface expression. Levels
of circulating CCR6þ , IL-23Rþ , and CD161þ CD4þ cells
did not significantly correlate with skin disease severity (see
Supplementary Figure S1a online).
To determine whether CCR6, IL-23R, and CD161 label the
same or unique populations of human CD4þ cells, cells
were then analyzed for simultaneous expression of all three
surface markers. Surprisingly, CCR6, IL-23R, and CD161 did
not consistently label the same cells (Figure 1b and c). There
were significantly more CCR6þ IL-23RþCD161þ cells,
CCR6þ IL-23RþCD161 cells, CCR6IL-23RþCD161þ
cells, and CCR6IL-23RþCD161 cells in psoriatics
compared with healthy individuals (2.58±1.56 vs
0.90±0.85%, Po0.01; 3.62±2.33 vs 1.44±0.86%,
Po0.05; 1.90±0.91 vs 1.05±0.72%, Po0.05; 11.8±3.04
vs 6.44±3.77%, Po0.01, respectively) (Figure 1c). By
contrast, there were fewer CCR6IL-23RCD161 cells in
psoriatics (67.5±8.07 vs 79.5±5.59%, Po0.001) (Figure 1c).
Circulating Th17 cells are increased in psoriasis, but do not
correlate with skin disease severity
As T cells immediately secrete cytokines on production
in vivo, intracellular detection of cytokines in these cells ex
vivo normally requires a brief stimulation period in the
presence of brefeldin A, which blocks protein secretion.
Thus, CD4þ cells were incubated with PMA and ionomycin
for 6 hours in the presence of brefeldin A. In single-color
analyses, IL-17Aþ , IL-22þ , and TNF-aþ cells were
elevated in psoriatics compared with healthy individuals
(1.47±0.74 vs 0.73±0.34%, Po0.001; 1.71±1.04 vs
1.00±0.31%, Po0.001; and 56.4±10.3 vs 41.4±10.2%,
Po0.001, respectively) (Figure 2a). IFN-gþ cells were also
elevated in psoriatics, but to a lesser extent (10.3±3.87 vs
7.55±2.58%, Po0.05) (Figure 2a). Cells were then analyzed
for simultaneous expression of IL-17A and IFN-g (Figure 2b
and c). Circulating IL-17Aþ IFN-g cells, a classic definition
of Th17 cells, were increased in psoriatics when compared
with healthy individuals (1.33±0.71 vs 0.66±0.28%,
Po0.001) (Figure 2c). IL-17AIFN-gþ and IL-17Aþ
IFN-gþ cells were also increased in psoriatics, indicating
elevations in Th1 and Th17/Th1 cells, but to a lesser extent
when compared with IL-17Aþ IFN-g cells (8.68±3.28 vs
6.07±1.81%, Po0.05 and 0.21±0.14 vs 0.11±0.07%,
Po0.01, respectively) (Figure 2b and c). Levels of circulating
IL-17Aþ , IL-22þ , IFN-gþ , and TNF-aþ CD4þ cells
did not significantly correlate with skin disease severity
(Supplementary Figure S1b).
Most circulating Th17 cells do not simultaneously express both
IL-17A and IL-22
To determine whether IL-17Aþ , IL-22þ , and IFN-gþ label
the same or unique populations of circulating human CD4þ
cells, cells were analyzed for simultaneous expression of all
three intracellular cytokines. Interestingly, IL-17A and IL-22
production did not consistently occur in the same cells,
whereas IL-17A and IFN-g production did not consistently
occur in separate cell populations (Figure 3a and b). For these
experiments, Th17 cells were defined as IL-17Aþ
IL-22þ IFN-g and IL-17Aþ IL-22IFN-g cells, and by
this definition, they were increased in blood of psoriatics
compared with healthy individuals (0.19±0.20 vs
0.07±0.04%, Po0.001 and 1.02±0.71 vs 0.52±0.25%,
Po0.001, respectively) (Figure 3b). By contrast, Th1
(IL-17AIL-22IFN-gþ ), Th17/Th1 (IL-17Aþ IL-22
IFN-gþ ), and Th22 (IL-17AIL-22þ IFN-g) cells were
increased to lesser degrees in psoriatics compared with
healthy individuals (8.84±3.11 vs 5.93±1.86%, Po0.01,
0.13±0.11 vs 0.05±0.03%, Po0.01, and 1.29±0.78 vs
0.86±0.32%, Po0.05, respectively) (Figure 3b). Circulating
Table 1. Demographics of healthy individuals and
untreated psoriatics evaluated in this study
Age of healthy individuals 34.0±13.0 years
Age of untreated psoriatics 42.3±12.0 years
PASI of untreated psoriatics 22.2±24.9
Abbreviation: PASI, Psoriasis Area and Severity Index.
Data are expressed as mean±SD.
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cells negative for all three of these cytokines were signifi-
cantly lower in psoriatics (88.3±4.12 vs 92.4±2.15%,
Po0.001) (Figure 3b), indicating a general trend toward
higher levels of inflammatory cytokine-producing CD4þ
cells in persons with psoriasis compared with those without
this disease.
IL-22 plasma levels are increased in psoriasis and correlate with
skin disease severity
Plasma levels of IL-17A, IL-22, IFN-g, and TNF-a were also
measured. Plasma IL-22 and TNF-a levels, but not IL-17A or
IFN-g levels, were significantly higher in psoriatics compared
with controls (Po0.001 for both) (Supplementary Figure S2a).
It is noted that IL-22 plasma levels correlated significantly
with PASI (r40.45 and Po0.05) (Supplementary Figure S2b).
Plasma levels of IL-17A, IFN-g, and TNF-a did not
significantly correlate with skin disease severity (Supplemen-
tary Figure S2b).
Based on IL-17A production, CCR6 is a more reliable cell
surface marker for circulating Th17 cells when compared
with IL-23R or CD161
Most of the scientific literature on the phenotype of
human Th17 cells is derived from experiments where naive
CD4þ T cells are induced to differentiate in vitro into
relatively pure polarized populations of Th17 clones, and
then examined for cell surface and cytokine expression
(Acosta-Rodriguez et al., 2007; Annunziato et al., 2007;
Cosmi et al., 2008). In contrast, we studied populations
of primary Th17, Th22, and Th1 cells isolated and analyzed
directly from human blood. These cells have been identified
within the pool of circulating CD4þCD45ROþ (memory)
T cells (Miossec et al., 2009). Th17 cells were first defined
as CD4þ cells that produced IL-17A and Th1 cells as
CD4þ cells that produced IFN-g. Populations of cells
producing IL-17A, IL-22, or IFN-g were then gated
and examined for expression of CCR6, IL-23R, CD161, and
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Figure 1. Circulating CCR6þ , IL-23Rþ , and CD161þ cells are increased in psoriasis. (a) The percentage of CD4þ cells expressing CCR6, IL-23R,
and CD161 among unstimulated cells from 17 healthy individuals and 21 untreated psoriatics (horizontal bars, mean; each circle, single donor).
(b) Representative dot plot analyses of CCR6, IL-23R, and CD161 expression in circulating unstimulated CD4þ cells from the same individual. (c) The
percentages of each subset divided by the total number of circulating CCR6, IL-23R, and CD161-positive cells in unstimulated CD4þ cells of healthy
individuals (white bars) and psoriatics (black bars). Data expressed as mean±SD; *Po0.05, **Po0.01, and ***Po0.001.
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TNF-a. Most IL-17Aþ cells and more than half of IL-22þ
cells expressed CCR6, whereas only a quarter of IFN-gþ
cells expressed CCR6 (80.9±12.4, 57.7±13.2, and
25.8±9.04%, respectively, Po0.001 when comparing
CCR6þ IL-17Aþ or CCR6þ IL-22þ cells with CCR6þ
IFN-gþ cells) (Figure 4). Surprisingly, only 23% of
IL-17Aþ cells expressed IL-23R, yet both IL-17Aþ and
IL-22þ cells were more likely to express IL-23R than IFN-gþ
cells (Po0.05 and Po0.001, respectively) (Figure 4). CD161
expression was significantly increased by IL-17Aþ cells
(58.6±15.0% for IL-17Aþ , 34.7±10.6% for IL-22þ , and
25.6±11.2% for IFN-gþ , respectively), but to a lesser extent
compared with CCR6 expression (Figure 4). IL-22þ cells were
less likely to produce TNF-a simultaneously compared with IL-
17Aþ or IFN-gþ cells (83.6±6.88% for IL-17Aþ ,
66.8±13.9% for IL-22þ , and 81.6±9.35% for IFN-gþ ,
respectively) (Figure 4). From these results, we conclude that
most primary human circulating Th17 cells express CCR6,
CD161, and TNF-a, whereas most primary human circulating
Th1 cells express TNF-a, but do not express CCR6 or CD161.
These data also suggest that CCR6 is a more reliable
cell surface marker when compared with IL-23R or CD161 to
help distinguish between circulating human Th17 and
Th1 cells.
Circulating CCR6þ IL-17Aþ , CCR6þ IL-22þ , and
CCR6þ TNF-aþ cells are increased in psoriatics when
compared with healthy individuals
CD4þ cell subsets in individuals with or without psoriasis
were then analyzed using combinations of cell surface
protein and intracellular cytokine expression. Circulating
CCR6þ IL-17Aþ , CCR6þ IL-22þ , and CCR6þ TNF-aþ
cells were greatly increased in psoriatics (1.19±0.66 vs
0.55±0.25%, 1.02±0.77 vs 0.42±0.21%, and 14.8±5.94
vs 8.65±3.26%, respectively, Po0.001 for all three subsets)
(Figure 5). IL-23Rþ IL-22þ (0.73±0.62 vs 0.17±0.07%)
and IL-23Rþ TNF-aþ cells (8.65±4.32 vs 3.64±2.75%),
but not IL-23Rþ IL-17Aþ cells, were increased in psoriatics
as well, but to a lesser extent (Po0.01 and Po0.05,
respectively) (Figure 5). Furthermore, CD161þ IL-17Aþ
(0.84±0.41 vs 0.45±0.22%) and CD161þ IL-22þ
(0.66±0.53 vs 0.28±0.14%), but not CD161þ TNF-aþ
cells, were significantly increased in psoriatics (Po0.01 for
both) (Figure 5).
NF-jB and STAT3 inhibition in vitro blocks cytokine production
by circulating Th17 and Th1 cells
Phorbol myristate acetate and ionomycin, which were
used to stimulate cytokine production in this study,
IL-17A *** *** * ***
4.70 0.06 7.67 0.12
0.99
IL-17A
healthy
IL-17A+IFN-γ–
*** * **
1.33
0.66
4
3
2
1
0
20
15
10
5
0
0.21
0.11
0.8
0.6
0.4
0.2
0.0
IL-17A–IFN-γ+
8.68
6.07
IL-17A+IFN-γ+
IL-17A
psoriasis
0.18
IL-22 IFN-γ
IF
N
-γ
IF
N
-γ
TNF-α
CD
4+
 c
el
ls 
(%
)
CD
4+
 c
el
ls 
(%
)
4
3
2
1
0
20
15
10
5
0
56.4
41.4
80
60
40
20
0
6
4
2
0
1.47 1.71
10.3
7.55
1.000.73
He
alt
hy
Ps
ori
as
is
He
alt
hy
Ps
ori
as
is
He
alt
hy
Ps
ori
as
is
He
alt
hy
Ps
ori
as
is
He
alt
hy
Ps
ori
as
is
He
alt
hy
Ps
ori
as
is
He
alt
hy
Ps
ori
as
is
c
Figure 2. Circulating Th17, Th1, and Th17/Th1 cells are increased in psoriasis. (a) In single-color flow analyses, circulating IL-17Aþ , IL-22þ , IFN-gþ , and
tumor necrosis factor (TNF)-alphaþ cells are increased in psoriasis patients. (b) Representative two-color dot plot analyses of IL-17A and IFN-g expression
in stimulated CD4þ cells from a healthy volunteer and a psoriasis patient. (c) The percentages of circulating Th17 (IL-17Aþ IFN-g), Th1 (IL-17AIFN-gþ ),
and Th17/Th1 (IL-17Aþ IFN-gþ ) cells among stimulated CD4þ cells from healthy individuals and psoriatics. For a and c, each circle, single donor; horizontal
bars, mean; and *Po0.05, **Po0.01, and ***Po0.001.
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are known to activate both NF-kB and STAT3 (Caspar-
Bauguil et al., 1999; Hartley and Cooper, 2000). Both
NF-kB and STAT3 have also have been implicated in
mediating IL-17A production in Th17 cells (Cho et al.,
2006). Thus, NF-kB or STAT3 pathways were inhibited by
adding specific pharmacologic inhibitors of these proteins
in vitro (parthenolide or stattic, respectively). These agents
blocked CD4þ cell production of IL-17A, IL-22, IFN-g, and
TNF-a equally well in both healthy individuals (n¼6) and
psoriatics (n¼ 4) (Figure 6). Observed effects were dose
dependent and the inhibitors did not decrease cell viability at
the indicated concentrations (Figure 6).
Infliximab induces modest decreases in circulating Th17 and
Th1 cells over time in a small cohort of psoriatics
Infliximab is a potent TNF-a chimeric mAb that is FDA
approved for severe psoriasis. Five of the 21 patients
evaluated in our study received infliximab at weeks 0, 2,
and 6, and also had serial 7-color flow cytometry performed
on circulating CD4þ cells at weeks 0, 2, 6, and 14 (blood
drawn just before each infusion). Infliximab therapy over time
led to improvement in skin disease scores in all patients
(Table 2). Relatively minor decreases in Th17 cells (CCR6þ ,
CCR6þ IL-17Aþ , CCR6þ IL-22þ , CCR6þTNF-aþ ) and
Th1 cells (IFN-gþ , IL-17AIFN-gþ , IFN-gþTNF-aþ ) were
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also seen in all five patients (Table 2), with a suggestion that
greater decreases occurred in Th17 cells compared with Th1
cells. Too few patients, however, were evaluated to generate
statistically significant differences in these parameters.
DISCUSSION
There are considerable data showing that both Th17 and Th1
cells are increased within involved psoriatic skin (Uyemura
et al., 1993; Szabo et al., 1998; Austin et al., 1999; Chan
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Figure 5. CCR6þ IL-17Aþ , CCR6þ IL-22þ , and CCR6þ TNF-aþ cells are increased in psoriatics compared with healthy individuals. Representative
two-color dot plot analyses of CCR6 and IL-17A/IL-22/tumor necrosis factor (TNF)-a expression in stimulated CD4þ cells from a single healthy volunteer (a)
and a psoriasis patient (b). (c) The percentages of circulating IL-17Aþ cells that coexpress CCR6, IL-23R, and CD161 among stimulated CD4þ cells from
healthy individuals and psoriatics. (d) The percentages of circulating IL-22þ cells that coexpress CCR6, IL-23R, and CD161 among stimulated CD4þ cells
from healthy individuals and psoriatics. (e) The percentages of circulating TNF-aþ cells that coexpress CCR6, IL-23R, and CD161 among stimulated CD4þ
cells from healthy individuals and psoriatics. Each circle, single donor; horizontal bars, mean; *Po0.05, **Po0.01, and ***Po0.001.
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et al., 2006; Wolk et al., 2006; Annunziato et al., 2007;
Wilson et al., 2007; Zaba et al., 2007; Kryczek et al., 2008;
Lowes et al., 2008; Harper et al., 2009). Here, we show clear
evidence of significant elevations in circulating Th17 cells in
psoriasis, using a number of criteria to define these cells.
More specifically, we show increases in circulating CCR6þ ,
IL-17Aþ , IL-22þ , IL-17Aþ IFN-g, CCR6þ IL-17Aþ ,
CCR6þ IL-22þ , CCR6þ TNF-aþ , IL-17Aþ IL-22þ
IFN-g, and IL-17Aþ IL-22IFN-g CD4þ T cells in
untreated psoriatics compared with healthy individuals
(Po0.001 for all subsets) (Figures 1–3 and 5). Circulating
Th1 cells, defined as IFN-gþ , IL-17AIFN-gþ , and
IL-17AIL-22IFN-gþ CD4þ cells, were also elevated
(Po0.05 for the first two subsets and Po0.01 for the third
subset) (Figures 2 and 3). It is noted that two groups recently
reported normal numbers of circulating Th17 cells in
psoriatics (Kryczek et al., 2008; Lowes et al., 2008). There
are three possible reasons for this discrepancy: (1) these
investigators used intracellular expression of IL-17A and IFN-
g alone to define Th17 cells (we used multiple criteria); (2)
CD4þ T cells were not purified before their analyses as we
have done; and (3) they studied smaller numbers of patients
and controls compared with our current report.
It is unknown how circulating Th17 cells in psoriasis
patients may contribute to skin disease and inflammation at
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Figure 6. NF-jB and STAT3 inhibition in vitro blocks cytokine production by both Th17 and Th1 cells in a dose-dependent manner. (a) CD4þ cells
were cultured overnight with or without parthenolide or stattic at the indicated concentrations, and then activated with phorbol myristate acetate (PMA)/
ionomycin for 6 hours. Representative two-color dot plot analyses of IFN-g and tumor necrosis factor (TNF)-a expression from a single healthy volunteer
are shown. (b) The percentage of circulating CD4þ cells producing IL-17A, IL-22, IFN-g, and TNF-a in healthy individuals (solid lines) and psoriatics (dotted
lines) with or without 2.5 mM of parthenolide or 1 mM of stattic. Each line, single donor.
Table 2. Decreases in skin disease severity scores and
circulating Th17 and Th1 cell numbers over time in
five psoriasis patients after initial treatment with
infliximab
Week 0
(%)
Week 2
(%)
Week 6
(%)
Week 14
(%)
PASI 7.7±6.31 5.6±3.0 4.0±2.6 3.7±2.4
Th17 markers
CCR6+ 16.4±3.40 15.4±2.71 14.2±3.84 10.4±3.17
CCR6+IL-17A+ 1.37±0.69 1.28±0.52 1.28±0.72 1.04±0.62
CCR6+IL-22+ 0.87±0.34 0.91±0.48 0.68±0.47 0.56±0.23
CCR6+TNF-a+ 16.3±2.24 13.5±2.05 13.4±1.84 12.4±3.97
Th1 markers
IFN-g+ 12.4±4.42 11.5±4.29 11.2±3.44 10.9±3.92
IFN-g+IL-17A 9.42±3.83 9.21±3.11 8.00±1.35 7.46±2.29
IFN-g+TNF-a+ 8.42±2.90 7.42±3.36 6.31±1.37 6.58±2.55
Abbreviations: PASI, Psoriasis Area and Severity Index; TNF, tumor
necrosis factor.
1Data are expressed as mean±SD.
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sites other than skin. They may represent cells that are
trafficking to and from skin, thus contributing significantly to
cutaneous inflammation. However, the xenograft transplan-
tation model of psoriasis, whereby human non-lesional skin
from psoriatics is engrafted onto immunodeficient mice, is
independent of circulating human T cells (Boyman et al.,
2004). Alternatively, and independent of skin disease
severity, psoriatics may be genetically predisposed to make
greater amounts of IL-23 and to create greater numbers of
Th17 cells under the appropriate stimulation conditions,
whether the cells are in the blood, skin, or elsewhere. This
genetic tendency could be regulated, at least in part, by
polymorphisms in IL-23p19, IL-12/23p40, and IL-23R (Nair
et al., 2009). Circulating Th17 cells could also have a role in
systemic inflammation observed in psoriasis patients, includ-
ing psoriatic arthritis and atherosclerosis (Gelfand et al.,
2006). Recent evidence suggests that Th17 cells and
cytokines promote atherosclerosis (Cheng et al., 2008; Eid
et al., 2009). Thus, we believe it would be important to study
correlations between numbers and functional activity of
circulating Th17 cells and the development of atherosclerosis
and/or myocardial infarction in individuals with severe
psoriasis.
Our data are strengthened by the utilization of 7-color
flow cytometry to simultaneously examine both cell surface
marker expression and intracellular cytokine expression in
various circulating T cell subsets. As there is no universal cell
surface marker to delineate Th17 cells from Th1 cells, we
used several criteria to help distinguish these two subsets.
CCR6 was expressed by 81% of circulating IL-17Aþ cells
and only 26% of circulating IFN-gþ cells, making it the best
cell surface marker we studied to delineate Th17 cells from
Th1 cells (Figure 4). By contrast, CD161 and IL-23R were
expressed by fewer circulating Th17 cells and by a minority
of circulating Th1 cells, which made them less useful markers
in separating these two T cell subsets (Figure 4). It is unclear
why so few IL-17Aþ cells expressed IL-23R, but this may
have been due to downregulation of cell surface receptor
expression following mitogenic stimulation of the cells. It is
also possible that stimulation of cells by IL-23, and not by
PMA/ionomycin, may be a more selective inducer of IL-17A
specifically within the population of IL-23Rþ Th17 cells.
Even though CCR6 was shown to be the best Th17 cell
surface marker used here, sensitivity and specificity were too
low for CCR6 to be used as a sole marker for Th17 cells.
Combining expression of CCR6 with intracellular cytokine
production may prove to be a useful tool in future analyses of
Th17 and Th1 cells in human disease. Very recently, the skin-
homing markers CCR4 and CCR10 have been identified on
blood-derived Th22 cells (Duhen et al., 2009; Trifari et al.,
2009). It will be interesting to further characterize Th22 and
Th17 subsets in blood of psoriatics for their expression of
cutaneous lymphocyte antigen, the prototypic skin-homing
marker, and these two chemokine receptors.
Little information is known about the function of Th17/Th1
cells and Th22 cells. Th17/Th1 cells were identified in the
affected skin of psoriatics (Lowes et al., 2008; Nograles et al.,
2009). Zaba et al. (2009) recently reported that dermal
dendritic cells within psoriasis lesions induce a population of
activated T cells that simultaneously produce IL-17A and
IFN-g (i.e., Th17/Th1 cells), which was not observed when
using dermal dendritic cells isolated from normal skin.
We show here that Th17/Th1 cells, defined as either
IL-17Aþ IFN-gþ or IL-17Aþ IL-22IFN-gþ cells, are a rare
population of circulating cells, representing only 0.05–0.11%
of CD4þ cells in healthy blood and 0.13–0.21% of CD4þ
cells in psoriatic blood (Po0.01 for both subsets) (Figures 2
and 3). Our data suggest that the tendency to develop Th17/
Th1 cells may be a general immunologic feature seen in
psoriasis patients, and not necessarily a phenomenon
restricted to inflamed skin. Another relatively obscure subset
of T cells, Th22 cells (defined as IL-17AIL-22þ IFN-g),
was more commonly detected when compared with Th17/
Th1 cells: 1.29% of CD4þ cells in psoriatic versus 0.86% of
CD4þ cells in healthy individuals (Po0.05) (Figure 3). The
clinical relevance of circulating Th22 cells remains to be
determined, although Liu et al. (2009) recently suggested that
these cells are preferentially stimulated by Candida albicans,
and thus may have a role in defense against fungal infections.
We also measured plasma cytokine levels, which have
been notoriously difficult in prior studies of psoriasis, as pro-
inflammatory cytokines are usually active and elevated only
at sites of tissue inflammation and not within circulation. We
showed that plasma IL-22 concentration is higher in
psoriatics when compared with healthy individuals and that
levels are highly reflective of skin disease activity (Supple-
mentary Figure S2), which is consistent with two previous
reports (Wolk et al., 2006; Caproni et al., 2009). We also
detected increases in plasma TNF-a (Supplementary
Figure S2), similar to several prior reports (Mussi et al.,
1997; Arican et al., 2005). In contrast to IL-22 and TNF-a, IL-
17A and IFN-g concentrations are not elevated in plasma of
psoriatics (Supplementary Figure S2a). Thus, despite some
conflicting data on serum or plasma cytokine data, there
appears to be consensus that circulating levels of IL-22 and
TNF-a are increased in psoriatics, and that cytokine
concentrations, especially for IL-22, correlate with extent of
skin disease activity.
NF-kB is important in regulating expression of a wide
variety of cytokines. Relevant to psoriasis, NF-kB expression
is high in affected skin and normalizes following effective
anti-psoriatic therapy with etanercept (Lizzul et al., 2005).
NF-kB regulates IL-17A production by inducing phosphor-
ylation of IkB-a (Cho et al., 2006). Here, we showed that
specific inhibition of NF-kB by parthenolide led to the
complete blockade of IL-17A, IL-22, IFN-g, and TNF-a
production by circulating CD4þ cells in vitro (Figure 6).
Importantly, IL-17A production by Th17 cells is critically
dependent on STAT3 activation through the PI3K pathway
(Cho et al., 2006). Furthermore, individuals with genetic
mutations in STAT3 develop Job’s syndrome, also known as
hyper-IgE syndrome, and are incapable of making Th17 cells
(Ma et al., 2008; Milner et al., 2008). Accordingly, we
showed that IL-17A, IL-22, IFN-g, and TNF-a production by
CD4þ cells could be completely blocked in vitro by stattic, a
specific inhibitor of STAT3 (Figure 6). Although systemic
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inhibition may be impractical on the basis of feasibility and
safety issues, skin-specific inhibition of either NF-kB or
STAT3 may be a future therapeutic strategy for patients with
localized psoriasis.
Infliximab is a chimeric anti-TNF-a mAb that is highly
efficacious in the treatment of individuals with moderate-to-
severe plaque psoriasis (Reich et al., 2005). Here, we serially
evaluated numbers of circulating Th17 and Th1 cells in five
patients receiving induction therapy with infliximab. Inflix-
imab led to decreases in clinical disease scores and
circulating levels of both Th17 and Th1 cells, including
Th17 and Th1 cells that produced TNF-a (Table 2). Drops in
both clinical and immunologic parameters, however, were
relatively minor and not statistically significant, although
there was a trend toward greater decreases in Th17 cell
numbers when compared to Th1 cell numbers. We believe
dramatic changes were not observed because the study
included too few patients and because of the potential
residual clinical and immunologic effects induced by
etanercept therapy, which these five patients were receiving
2–4 weeks before their first infliximab infusion. Thus, greater
decreases in circulating Th17 and Th1 cells may have been
observed if the patients showed more severe skin disease and/
or were treatment naive at the beginning of the study. It will
be interesting to monitor circulating levels of Th17 and Th1
cells in patients receiving ustekinumab or ABT-874, two new
highly effective human mAb therapies for moderate-to-severe
psoriasis that target p40 (Kimball et al., 2008; Leonardi et al.,
2008; Papp et al., 2008), the subunit shared by IL-23 and IL-
12. Drops in circulating levels of both Th17 and Th1 cells are
expected, although it is unclear whether this will lead to
decreases in systemic immune function.
MATERIALS AND METHODS
Study subjects and sample collection
The Oregon Health and Science University Institutional Review
Board approved all aspects of this study according to the Declaration
of Helsinki Principles. After giving informed consent, 17 healthy
individuals and 21 untreated psoriatics were enrolled. Of these 21
patients, five were also enrolled in a 22-week open-label study to
determine the efficacy of infliximab in treating psoriasis in patients
who had previously failed etanercept therapy. These individuals
were eligible for the study if they had active psoriasis lesions while
on etanercept; etanercept therapy for psoriasis was stopped 2–4
weeks before starting infliximab. Each of these patients received
intravenous infusions of infliximab 5mg kg1 at weeks 0, 2, 6, 14,
and 22, a dose of infliximab previously shown to be highly effective
for psoriasis (Reich et al., 2005). Blood was isolated for T cell
analyses just before infusions on weeks 0, 2, 6, and 14. Each time
blood was collected from a psoriasis patient, Psoriasis Area and
Severity Index (PASI) was determined, which is a standard measure
of psoriasis clinical disease activity.
Fifty microliters of blood was collected from each study subject in
EDTA-coated blood collection tubes (BD Biosciences, San Jose, CA).
Blood samples were diluted 1:2 with phosphate-buffered saline
and peripheral blood mononuclear cells were isolated through
Ficoll-hypaque (Amersham, Piscataway, NJ) gradient centrifugation.
Plasma samples were collected and stored at 20 1C until further
use. CD4þ cells were then purified from peripheral blood mono-
nuclear cells by negative selection using the EasySep human CD4þ
T cell enrichment kit (Stemcell, Vancouver, Canada).
Antibody reagents
The following mouse anti-human mAbs and corresponding isotype
control Abs were used for flow cytometry: phycoerythrin (PE)-
conjugated IL-17A (BioLegend, San Diego, CA), Pacific Blue-
conjugated IL-17A (BioLegend), PE-conjugated IL-22 (R&D Systems,
Minneapolis, MN), PE-conjugated IFN-g (BD Biosciences), PerCP-
Cy5.5-conjugated IFN-g (BioLegend), PE-conjugated TNF-a (R&D
Systems), PE-Cy7-conjugated TNF-a, (BD Biosciences), allophyco-
cyanin-conjugated CCR6 (R&D Systems), FITC-conjugated CD161
(BD Biosciences), allophycocyanin-H7-conjugated CD4 (clone
RPA-T4, BD Biosciences). The goat antihuman polyclonal biotiny-
lated IL-23R Ab (R&D Systems), FITC streptavidin (eBioscience, San
Diego, CA), and PE streptavidin (eBioscience) were used for IL-23R
labeling.
Flow cytometry on circulating CD4þ cells
Blood-derived CD4þ cells were resuspended at 5 105 cellsml1
in RPMI 1640 with GlutaMAX-I (Invitrogen, Grand Island, NY)
containing 5% human AB serum (Sigma, St Louis, MO), 100Uml1
of penicillin G sodium, and 100mgml1 of streptomycin sulfate
(Invitrogen). CD4þ cells were cultured overnight (B14 hours) in
six-well plates (Corning, Corning, NY) at 37 1C and 5% CO2 with or
without 2.5 mM of parthenolide (NF-kB inhibitor, EMD Biosciences,
La Jolla, CA) or 1 mM of stattic (STAT3 inhibitor, EMD Biosciences).
The following morning, CD4þ cells were stimulated for 6 hours
using 25 ngml1 of PMA and 1mgml1 of ionomycin in the presence
of 0.5 ml ml1 of BD GolgiPlug (BD Biosciences). Cells were then
centrifuged, washed, and resuspended in staining buffer (1% fetal
bovine serum and 0.09% sodium azide solution in phosphate-
buffered saline). Cells were incubated with mAbs for extracellular
proteins for 30minutes at 4 1C, washed twice with staining buffer,
and incubated with fluorochrome-conjugated streptavidin for
30minutes at 4 1C. Cells were then washed twice, fixed, and
permeabilized using the Cytofix/Cytoperm kit (BD Biosciences)
according to the manufacturer’s instructions. Cells were then
incubated with antibodies for intracellular cytokines for 30minutes
at 4 1C. Cells were collected using an LSRII flow cytometer equipped
with FACSDiva (BD Biosciences) and analyzed with FlowJo software
(Treestar, Ashland, OR). As CD4þ cells were purified on day 0,
percentages of CD4þ cells that express any given cell surface or
intracellular protein also reflect absolute increases in cells expres-
sing that protein. It is noted that memory T cell populations were not
specifically selected in our experiments, but instead CD4þ T cell
populations that contained both naive and memory cells were
analyzed.
Intracellular cytokines were not expressed in uncultured cells
isolated on day 0 (data not shown). In a subset of initial experiments,
CCR6 surface expression following 1 versus 5 days of culture was
compared. CCR6 expression decreased considerably to undetectable
levels with additional days of culture (data not shown), and thus the
5-day culture experiments were abandoned. In another series of
initial experiments, blood samples were obtained from the same
healthy volunteers on different days to establish reproducibility of
the flow cytometry (data not shown). As the psoriasis patients were
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often initiating therapies after having blood samples drawn for this
study, data reproducibility on different days could not be established
for these individuals.
ELISA
Frozen plasma was allowed to thaw and IL-17A, IL-22, IFN-g, and
TNF-a levels were measured by ELISA (RayBiotech, Norcross, GA for
IL-17A and IFN-g; Quantikine ELISA kit, R&D systems for IL-22, and
Quantikine HS ELISA kit, R&D systems for TNF-a), according to the
manufacturer’s instructions. Optical densities were measured at
450 nm for IL-17A, IL-22, and IFN-g and 490nm for TNF-a with a
microplate spectrophotometer (Spectramax Plus, Molecular Devices,
Sunnyvale, CA). Concentrations were calculated from the standard
curves generated by SOFTmax Pro (Molecular Devices).
Statistical analyses
The w2 goodness-of-fit test was used to evaluate normality for all
parameters. The F-test and Bartlett test were used to evaluate
equality of variance between two and three groups, respectively. The
Student’s t-test was used when data were normally distributed and
variance was equal. Welch’s t-test was used when data were
normally distributed and variance was not equal. Mann–Whitney’s
U-test was used when data were not normally distributed.
Regression lines were calculated with the least squares method.
Spearman’s correlation coefficient by rank test was used to evaluate
correlations between two sets of data. For multiple comparisons as
shown in Figure 4, the two-factor analysis of variance and Scheffe’s
F tests were used when data were normally distributed and the
variance was equal, whereas the Friedman and Scheffe’s F tests were
used when the data were not normally distributed or the variance
was not equal. P-values of 0.05 or less were considered significant.
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